证券代码：002393 证券简称：力生制药 公告编号：2023-024 本公司及其董事、监事、高级管理人员保证公告内容真实、准确和完整，公告不 存在虚假记载、误导性陈述或者重大遗漏。 公司定于2023年05月23日(周二）下午15:00～17:00在全景网举办2022年度业绩说明 会，本次年度业绩说明会将采用网络远程方式举行，投资者可登陆全景网"投资者关系互动 平台"（http://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：董事长张平先生、独立董事方建新先生、财务总监王家颖先 生、董事会秘书马霏霏女士。 天津力生制药股份有限公司 关于举办2022年度报告网上业绩说明会的通知 （问题征集专题页面二维码） 特此公告。 天津力生制药股份有限公司 董事会 2023 年 5 月 13 日 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前向投资者公 开征集问题，广泛听取投资者的意见和建议。投资者可于2023年05月22日（周一）15:00前 访问http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面。敬请广大投资者通过 全景网系统提交您所关注 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 335,604,291, representing a 9.51% increase compared to CNY 306,461,015 in the same period last year[5] - Net profit attributable to shareholders was CNY 46,500,336, marking a 10.84% increase from CNY 41,953,999 in the previous year[5] - Basic and diluted earnings per share were both CNY 0.25, up 8.70% from CNY 0.23 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 335,604,291, an increase of 9.5% compared to CNY 306,461,015.93 in Q1 2022[21] - Net profit for Q1 2023 reached CNY 46,500,336.40, representing a 10.1% increase from CNY 41,953,999.32 in Q1 2022[22] - The company reported a total comprehensive income of CNY 46,500,336.40 for Q1 2023, compared to CNY 41,953,999.32 in the same period last year[22] Cash Flow and Investments - The net cash flow from operating activities reached CNY 57,529,078, a significant increase of 75.03% compared to CNY 32,867,367 in Q1 2022[5] - Operating cash inflow totaled CNY 279,472,368.80, an increase of 31.43% compared to the previous year[12] - Cash outflow from investment activities amounted to CNY 83,213,283.93, an increase of 526.80% compared to the same period last year, primarily due to the purchase of financial products[14] - Net cash flow from investment activities reached CNY 123,218,552.48, an increase of 1028.14% year-on-year, driven by the redemption and purchase of financial products[14] - Net increase in cash and cash equivalents was CNY 180,747,631.06, reflecting an increase of 822.58% compared to the previous year, mainly due to the redemption of financial products and increased cash receipts from sales[14] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,359,705,857, reflecting a 1.30% increase from CNY 5,291,039,548 at the end of the previous year[5] - Total current assets at the end of the reporting period amounted to CNY 2,636,640,710.20, slightly up from CNY 2,625,403,269.58 at the beginning of the year[18] - Total liabilities amounted to CNY 945,597,383.38, an increase from CNY 941,660,896.69 at the beginning of the year[19] - The company’s long-term equity investments increased to CNY 76,639,709.29 from CNY 72,501,812.44 at the beginning of the year[18] - The company’s total equity attributable to shareholders increased by 1.49% to CNY 4,414,108,473.96 compared to the end of the previous year[5] Shareholder Information - Total number of common shareholders at the end of the reporting period is 18,544[14] Research and Development - Research and development expenses for Q1 2023 were CNY 23,927,742.21, a decrease from CNY 25,726,028.46 in Q1 2022[21] Other Information - The company did not report any new product launches or significant market expansion strategies during the quarter[27]

【2023 年３月】 1 天津力生制药股份有限公司 2022 年年度报告全文 天津力生制药股份有限公司 2022 年年度报告全文 天津力生制药股份有限公司 2022 年年度报告 2022 年年度报告 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别 和连带的法律责任。 公司负责人张平、主管会计工作负责人王家颖及会计机构负责人(会计主 管人员)高峻声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展陈述，属于计划性事项，不构成公司对投资者 的实质承诺，敬请投资者注意投资风险。 1.行业政策变化风险 国家医疗体制改革持续深化，实施带量采购、一致性评价、医保控费、 两票制、安全环保升级等政策，给公司经营发展带来挑战，对药品研发、生 产、销售产生较大影响。对此，公司将持续加强合规管理，密切关注，及时 调整经营策略，推进提质增效工作，提升经营质量和经营效率，推动公司持 续发展。 2.研发及转型风险 公司致力于通过研发创新促进公司的转型升级，由于 ...

天津力生制药股份有限公司 2022 年第三季度报告 天津力生制药股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报 告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 天津力生制药股份有限公司 2022 年第三季度报告 证券代码：002393 证券简称：力生制药 公告编号：2022-067 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 同期增减 | | 比上年同期增减 | | 营业收入（元） | 287,280,219.99 | 15.69% | ...

证券代码：002393 证券简称：力生制药 公告编号：2022-052 天津力生制药股份有限公司 关于举行"2022 年度天津辖区上市公司半年报业绩 说明会与投资者网上集体接待日"活动的公告 本公司及其董事、监事、高级管理人员保证公告内容真实、准确和完整，公告不 存在虚假记载、误导性陈述或者重大遗漏。 天津力生制药股份有限公司定于2022年9月6日（周二）13:40-16:40在全景网举行"2022 年度天津辖区上市公司半年报业绩说明会与投资者网上集体接待日"活动，本次活动将采用 网络远程的方式举行，投资者可登录"全景路演"（http://rs.p5w.net）参与本次互动交流。 出席本次活动的人员有：董事长徐道情先生、财务总监王家颖先生、董事会秘书马霏霏 女士。 欢迎广大投资者积极参与本次网上说明会。 特此公告。 天津力生制药股份有限公司 董事会 2022 年 9 月 2 日 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥614,740,089.46, representing a 4.67% increase compared to ¥587,330,610.63 in the same period last year[33]. - The net profit attributable to shareholders was ¥71,953,889.11, up 17.47% from ¥61,252,788.63 year-on-year[33]. - The net cash flow from operating activities surged by 217.75%, reaching ¥127,419,970.23 compared to ¥40,101,105.63 in the previous year[33]. - The basic earnings per share increased by 14.71% to ¥0.39 from ¥0.34 in the same period last year[33]. - Total assets at the end of the reporting period were ¥5,354,608,124.42, a 3.15% increase from ¥5,190,932,494.57 at the end of the previous year[33]. - Total profit reached 89 million yuan, reflecting an 18.50% growth year-over-year, while net profit was 72 million yuan, up 17.47%[53]. - The total assets increased by 3.15% to 5.355 billion yuan, and net assets grew by 0.45% to 4.431 billion yuan[53]. - The company achieved a consolidated revenue of 615 million yuan in the first half of 2022, an increase of 4.67% compared to the previous year[53]. - The company reported a total non-recurring profit and loss of 385,033.45 yuan after accounting for government subsidies and other income[38]. Research and Development - There is a significant investment in R&D for new products, particularly in the cardiovascular and chronic disease sectors, to counteract the anticipated decline in generic drug prices[13]. - Research and development investment rose by 7.71% to 64.5 million yuan, supporting the company's innovation efforts[72]. - The company aims to enhance its innovation capabilities, with expectations to obtain one more consistency evaluation approval and to submit additional applications for generic drugs[64]. - The company is focusing on R&D innovation to drive transformation, despite the long and uncertain nature of drug development cycles[104]. - The company is focusing on enhancing its research and development capabilities to innovate and introduce new technologies[200]. Market Strategy and Compliance - The company plans to enhance compliance management and adjust operational strategies in response to ongoing national healthcare reforms and procurement policies[8]. - The company is focusing on accelerating the consistency evaluation of its generic drugs to maintain market competitiveness amid expanding centralized procurement[10]. - The company emphasizes a dual-driven approach of production operations and capital operations to increase development momentum[47]. - The company is focusing on innovation and compliance management to adapt to the evolving pharmaceutical regulatory environment[42]. - The company has established a comprehensive risk control system to ensure safety, quality, and compliance in operations[66]. Environmental Compliance - Tianjin Lisheng Pharmaceutical Co., Ltd. reported a total wastewater discharge of 1.756 tons for chemical oxygen demand, exceeding the limit of 44.55 tons[116]. - The company recorded a total nitrogen discharge of 0.412 tons, with a limit of 7.303 tons, indicating compliance with environmental standards[116]. - The ammonia nitrogen discharge was 0.017 tons, well below the limit of 2.903 tons, demonstrating effective pollution control measures[116]. - The company has implemented measures to ensure that all emissions are within the prescribed limits, demonstrating commitment to environmental sustainability[116]. - The company has obtained environmental permits for multiple projects, including the expansion project and the addition of raw material drug varieties[118]. Investment and Asset Management - The company plans to accelerate the transfer of low-efficiency assets and is actively seeking potential buyers for its biopharmaceutical vaccine project[62]. - The company has a remaining unused fundraising amount of CNY 80,739,280, which is stored in a dedicated fundraising account[89]. - The company has invested CNY 39,007,000 in the Tianjin New Crown Pharmaceutical Co., Ltd. project, achieving a progress rate of 97.15%[92]. - The company has completed the acquisition of a 48% equity stake in a biochemical pharmaceutical company for CNY 3,536,000, achieving 100% of the investment commitment[92]. - The company plans to use 100.70 million yuan to replace self-raised funds previously invested in projects[95]. Risks and Challenges - The company faces risks from industry policy changes, including national medical system reforms and procurement policies, which may impact drug development and sales[102]. - There is a risk related to the completion of consistency evaluations for generic drugs, which could affect market competitiveness if not addressed[103]. - Rising production costs due to stricter standards and raw material price increases pose a significant risk to the company's operations[105]. - The implementation of national procurement policies is expected to lead to a decline in drug prices, increasing sales pressure on the company[106]. Corporate Governance and Shareholder Information - The company has not made any significant changes to the use of raised funds during the reporting period[90]. - The company reported a total guarantee amount of 4,000 million CNY during the reporting period, with the actual guarantee balance also at 4,000 million CNY[144]. - The company has no significant related party transactions during the reporting period, including asset or equity acquisitions and joint external investments[134][135]. - The company reported a total of 182,454,992 shares outstanding, with 100% being unrestricted shares[154]. - The total number of ordinary shareholders at the end of the reporting period was 18,781[156].

天津力生制药股份有限公司 2022 年第一季度报告全文 证券代码：002393 证券简称：力生制药 公告编号：2022-025 天津力生制药股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期 | | --- | --- | --- | --- | | | | | 增减 | | 营业收入（元） | 306,461,015.93 | 327,607,280.27 | -6.45% | | 归属于上市公司股东的净利润 | 41,953,999.32 | ...

天津力生制药股份有限公司 2021 年年度报告全文 天津力生制药股份有限公司 2021 年年度报告 2022 年 03 月 1 天津力生制药股份有限公司 2021 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人徐道情、主管会计工作负责人王家颖及会计机构负责人(会计主 管人员)王家颖声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展陈述，属于计划性事项，不构成公司对投资者的 实质承诺，敬请投资者注意投资风险。 1、行业政策变化风险 国家医疗体制改革持续深化，实施带量采购、一致性评价、医保控费、两 票制、安全环保升级等政策，给公司经营发展带来挑战，对药品研发、生产、 销售产生较大影响。对此，公司将持续加强合规管理，密切关注，及时调整经 营策略，推进提质增效工作，提升经营质量和经营效率，推动公司持续发展。 2、仿制药质量和疗效一致性评价工作按期完成的风险 随着全国药品集中采购扩面、扩品种持 ...

天津力生制药股份有限公司 2021 年第三季度报告 证券代码：002393 证券简称：力生制药 公告编号：2021-038 天津力生制药股份有限公司 2021 年第三季度报告 本公司及其董事、监事、高级管理人员保证公告内容真实、准确和完整，公告不存在 虚假记载、误导性陈述或者重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中 财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年 同期增减 | 年初至报告期末 | 年初至报告期末 比上年同期增减 | | --- | --- | --- | --- | --- | | 营业收入（元） | 248,328,474.55 | -17.66% | 835,659,085.18 | -8.71% | | ...

天津力生制药股份有限公司 2021 年半年度报告全文 天津力生制药股份有限公司 2021 年半年度报告 2021 年 08 月 1、行业政策变化风险 国家医疗体制改革持续深化，实施带量采购、一致性评价、医保目录调整、 医保控费、两票制、安全环保升级等政策，给公司经营发展带来挑战，对药品 研发、生产、销售产生较大影响。对此，公司将持续加强合规管理，密切关注， 及时调整经营策略，推进提质增效工作，提升经营质量和经营效率，推动公司 持续发展。 2、仿制药一致性评价工作及时完成的风险 随着全国药品集中采购扩面、扩品种持续推进，将倒逼医药生产企业加速一 致性评价工作。如果药品一致性评价工作未达预期，企业将丧失市场竞争机会， 市场份额面临被蚕食的风险。力生制药仿制药数量多，一致性评价费用负担大， 更面临关键品种时间紧迫的风险。公司将强化科研项目管理，在组织保障、研 发团队、资金配套、外部协作等方面，全力推进一致性评价工作开展。 1 天津力生制药股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈 ...